Enliven Therapeutics GAAP EPS of -$0.49 beats by $0.04

* Enliven Therapeutics press release [https://seekingalpha.com/pr/20200151-enliven-therapeutics-reports-second-quarter-financial-results-and-provides-a-business-update] (NASDAQ:ELVN [https://seekingalpha.com/symbol/ELVN]): Q2 GAAP EPS of -$0.49 beats by $0.04.
* As of June 30, 2025, the Company had cash, cash equivalents and marketable securities totaling $490.5 million, which is expected to provide cash runway into the first half of 2029.

MORE ON ENLIVEN THERAPEUTICS

* Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering [https://seekingalpha.com/news/4457887-enliven-therapeutics-stock-falls-after-pricing-capital-raise-of-200m-via-securities-offering]
* Seeking Alpha’s Quant Rating on Enliven Therapeutics [https://seekingalpha.com/symbol/ELVN/ratings/quant-ratings]
* Historical earnings data for Enliven Therapeutics [https://seekingalpha.com/symbol/ELVN/earnings]
* Financial information for Enliven Therapeutics [https://seekingalpha.com/symbol/ELVN/income-statement]